GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » Research & Development

TC BioPharm (Holdings) (TC BioPharm (Holdings)) Research & Development : $4.36 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. TC BioPharm (Holdings)'s Research & Development for the three months ended in Mar. 2024 was $1.65 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $4.36 Mil.

TC BioPharm (Holdings) Research & Development Historical Data

The historical data trend for TC BioPharm (Holdings)'s Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) Research & Development Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
11.29 8.98 8.19 9.25 9.84

TC BioPharm (Holdings) Quarterly Data
Dec19 Sep20 Dec20 Jun21 Sep21 Dec21 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.35 2.71 - 1.65

TC BioPharm (Holdings) Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TC BioPharm (Holdings)  (NAS:TCBP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TC BioPharm (Holdings) Research & Development Related Terms

Thank you for viewing the detailed overview of TC BioPharm (Holdings)'s Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

TC BioPharm (Holdings) (TC BioPharm (Holdings)) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » Research & Development
Comparable Companies
XTER:T5O OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX SZSE:300122 BGNE ALNY OCSE:GMAB BMRN XKRX:068270 XBRU:UCB RPRX INCY
Traded in Other Exchanges
T0U:Germany
Address
Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
Website
https://www.tcbiopharm.com
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.
Executives
Renaissance Capital Partners Ltd 10 percent owner 42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD